State of New Jersey Common Pension Fund D Trims Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

State of New Jersey Common Pension Fund D trimmed its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 42.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 48,943 shares of the biopharmaceutical company’s stock after selling 35,879 shares during the period. State of New Jersey Common Pension Fund D owned 0.09% of Agios Pharmaceuticals worth $2,110,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new stake in Agios Pharmaceuticals during the second quarter valued at about $37,000. Quest Partners LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at $40,000. NEOS Investment Management LLC purchased a new position in Agios Pharmaceuticals in the fourth quarter valued at about $210,000. North Star Asset Management Inc. acquired a new position in shares of Agios Pharmaceuticals during the second quarter worth about $216,000. Finally, Northcape Wealth Management LLC acquired a new position in shares of Agios Pharmaceuticals during the second quarter worth about $244,000.

Insider Transactions at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at $3,368,358. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Stock Down 1.8 %

Shares of AGIO stock opened at $46.55 on Friday. The business has a 50 day moving average of $45.69 and a two-hundred day moving average of $39.03. The company has a market cap of $2.64 billion, a P/E ratio of -7.50 and a beta of 0.75. Agios Pharmaceuticals, Inc. has a 52 week low of $19.80 and a 52 week high of $50.35.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The firm had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The firm’s revenue was up 28.4% on a year-over-year basis. During the same period last year, the business earned ($1.51) EPS. Analysts expect that Agios Pharmaceuticals, Inc. will post -4.85 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on AGIO shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $46.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. Royal Bank of Canada restated an “outperform” rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday. The Goldman Sachs Group lifted their price objective on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a report on Tuesday, June 4th. Finally, StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Agios Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $51.33.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.